Supernus Q3: Revenue $226.8M, EPS $0.35; Indivior Merger Closes November 2
SUPN is trading near its 52-week low of $37.54 (11% above the low) on elevated volume (2.1× avg).
Summary
Supernus reported Q3 2026 revenue of $226.8 million and diluted EPS of $0.35, with $359.5 million in cash and securities. The Indivior merger, approved by stockholders October 15, is expected to close November 2 with a $650 million term loan funding part of the deal.
Key Events · Earnings and Guidance · SUPN
-
Q3 Revenue $226.8M, EPS $0.35
Total revenues rose 18% year over year to $226.8 million, with net earnings of $20.9 million and diluted EPS of $0.35; nine-month revenue reached $653.5 million.
-
Nine-Month Net Loss on Impairment
The first nine months produced a net loss of $39.8 million versus $34.4 million a year earlier, driven by $56.5 million of impairment charges, including the $54.9 million APOKYN write-down.
-
Cash and Securities of $359.5M
Cash, cash equivalents and marketable securities totaled $359.5 million at September 30, 2026, with $68.3 million of operating cash flow in the first nine months.
-
Indivior Merger Closes November 2
Stockholders approved the merger on October 15, 2026; each Supernus share converts into a fixed 1.5401 Indivior shares, and a $650 million senior secured term loan is expected to be drawn at closing.
Analysis · SUPN · Life Sciences
The quarter itself was already public this morning via the 8-K, so the headline numbers are not new. What the 10-Q adds is the full balance sheet and cash flow picture — $359.5 million of cash and securities against a $39.8 million nine-month net loss that was driven by the $56.5 million of impairment charges, mostly the $54.9 million APOKGO write-down taken in Q2. The bigger item is timing: stockholders approved the all-stock Indivior merger on October 15, closing is set for November 2, and the combined company will draw a $650 million senior secured term loan at closing while the old $150 million UBS line was terminated in October. For anyone still holding SUPN, the shares convert at a fixed 1.5401 Indivior ratio, so the remaining question is the Indivior share price at close, not Supernus's standalone earnings.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SUPN was trading at $41.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $37.54 to $59.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.